go-v.orgdoi

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, PK, and PD of BG9924 When Given in Combo With MTX to Subjects With Active RA Who Have Had an Inadequate Response to Anti-TNF

Biogen · Vivli · 2021

  • DOI 10.25934/00007168
  • Publisher Vivli
  • Type dataset
  • Issued 2021

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Vivli · Vivli · dataset · 2021

Abstract

This Phase 2b study is designed to evaluate the efficacy and safety of BG9924 given subcutaneously (SC) versus placebo in participants with active rheumatoid arthritis (RA) who have previously had an inadequate response to treatment with anti-tumor necrosis factor (anti-TNF) therapy.

Open the resolved locator · 10.25934/00007168

Metadata licence: OpenAlex metadata (CC0)